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BACKGROUND: The optimal situation in external quality assessment (EQA) is to use 
commutable materials. No previous study has examined the commutability of a whole-blood 
material for point-of-care (POC) testing. The aim of this study was to determine the 
commutability of the Norwegian Quality Improvement of Laboratory Examinations (Noklus) 
organization’s “in-house” whole-blood EQA material for C-reactive protein (CRP), glucose, 
and hemoglobin for frequently used POC instruments in Norway and to determine the 
possibility of using a common target value for each analyte.  
METHODS: The study was performed according to the Clinical and Laboratory Standards 
Institute guidelines. The EQA material was pooled stabilized EDTA venous whole-blood 
containing different concentrations of the analytes. The EQA material and native routine 
patient samples were analyzed using 17 POC and 3 hospital instruments. The commutability 
was assessed using Deming regression analysis with 95% prediction intervals for each 
instrument comparison.  
RESULTS: The EQA material was commutable for all CRP and hemoglobin POC 
instruments, whereas for glucose the material was commutable for all POC instruments at the 
lowest concentration analyzed [126.0 mg/dL (7.0 mmol/L)] and for 3 POC instruments at all 
of the concentrations analyzed. 
CONCLUSIONS: Noklus EQA participants using CRP and hemoglobin POC instruments 
now receive results that are compared with a reference target value, whereas the results for 
participants using glucose POC instruments are still compared with method-specific target 
values. Systematic deviations from a reference target value for the commutable glucose POC 
instruments can be calculated, and this additional information can now be offered to these 




The quality of point-of-care (POC) testing can be monitored regularly by participating in an 
external quality assessment (EQA) scheme (EQAS). The extent to which an EQA provider is 
able to assess the performance of participants and instruments depends on several factors, 
including the quality of the EQA material used. The optimal situation is to use EQA material 
that is commutable, meaning that the EQA samples have the same numeric relationship 
between 2 measurement methods as a panel of representative patient samples (1). When a 
commutable EQA material is circulated to the participants, the probability of detecting true 
analytical errors increases, as well as the possibility of assessing the between-measurement 
methods variation. If a reference method or reference material is used to assign the target 
value, the participant results can be compared with a true value (2). The increasing interest in 
the harmonization and standardization of instruments has also led to an increased interest in 
using EQASs to assess the agreement of results between different measurement methods (1).  
 
Using a commutable EQA material is important for identifying analytes that need to be 
standardized and harmonized, and for monitoring the success of the standardization and 
harmonization efforts (3, 4). To assess the commutability of the whole-blood EQA material 
used in the present study, we used the method delineated in the Clinical and Laboratory 
Standards Institute (CLSI) Guideline EP14-A3 (1). 
 
The Norwegian Quality Improvement of Laboratory Examinations (Noklus) organization 
provides EQA programs for most analytes used in primary health care (5). The approximately 
3100 participants who are voluntarily enrolled in the programs come mainly from general-
practitioners clinics and nursing homes (6).  
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C-reactive protein (CRP), glucose, and hemoglobin (Hb) are among the most commonly 
performed laboratory tests in primary health care in Norway. All Noklus participants 
analyzing CRP, glucose, and Hb receive EQA material manufactured “in-house” by Noklus 
that consists of fresh stabilized venous whole-blood. The EQAS is performed biannually, and 
in each survey the participants receive 2 samples with different concentrations of the 3 
analytes.  
 
To our knowledge, the commutability of whole-blood EQA material for POC instruments has 
not been demonstrated previously. The aim of the present study was to determine the 
commutability of the Noklus whole-blood EQA material for CRP, glucose, and Hb for the 
most frequently used POC instruments in primary healthcare in Norway, and to investigate 
the possibility of using a common EQA target value for each analyte. 
 
Material and Methods 
INSTRUMENTS 
This study included 5 CRP, 7 glucose, and 5 Hb POC instruments (Table 1) that are the most 
commonly used POC instruments for these analytes in Norway. One accredited hospital 
instrument for CRP and glucose (Cobas 6000, Roche Diagnostics) and another accredited for 
Hb (Advia 2120, Siemens Healthcare)— both of which are available at the laboratory at 
Haraldsplass Deaconess Hospital (Bergen, Norway)— were included as the comparison 
instruments in the present study (1). The hospital instruments have been assessed through 
EQASs and have documented good analytical quality. The ERM/DA474/IFCC certified 
reference material (CRP in processed human serum) and the standard reference material SRM 
965b (glucose in frozen human serum) were used to validate the trueness of the Cobas 6000 
instrument in the present study (7, 8). 
 5 
WHOLE-BLOOD EQA MATERIAL 
The commutability studies were performed in association with the Noklus EQASs in 2014 
(CRP and glucose) and 2015 (Hb). The EQA material was manufactured by Noklus to cover 
the clinically relevant concentration ranges: 2 concentrations of Hb and 3 concentrations of 
CRP and glucose. 
 
To produce the EQA material, AB0-compatible EDTA venous whole-blood from healthy 
blood donors was collected from the blood bank at Haukeland University Hospital (Bergen, 
Norway). At Noklus (Haraldsplass Deaconess Hospital) the whole-blood was pooled, and 
plasma or erythrocytes were added to achieve Hb concentrations of 9.6 and 13.2 g/dL; human 
CRP (in.vent Diagnostica) was added to achieve CRP concentrations of 23, 58, and 73 mg/L; 
and D(+)-glucose monohydrate dissolved in sodium chloride (VWR) was added to achieve 
glucose concentrations of 126.0, 234.0, and 306.0 mg/dL (7.0, 13.0, and 17.0 mmol/L). 
Finally, iodoacetic acid sodium salt (VWR) and chloramphenicol succinate (VWR) were 
added to stabilize the glucose concentration and prevent bacterial growth. The whole-blood 
material was stored overnight in a refrigerator before distributed into 2-mL cryovials 
(Sarstedt) and stored at room temperature until the next day. The stability and homogeneity 
were tested according to ISO 13528 (9). 
 
An overview of the procedures of the commutability studies is shown in Fig. 1. 
 
PATIENT SAMPLES 
At the laboratory of Haraldsplass Deaconess Hospital, 22 CRP and 25 Hb routine patient 
samples were collected during a single day. All CRP and Hb patient samples were “leftover” 
samples form the laboratory where CRP and Hb had been requested. The patient samples 
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were selected to cover the concentration range of the EQA material, with a range of 10 to 119 
mg/L for CRP and 7.9 to 16.1 g/dl for Hb.  
 
For glucose, fresh capillary whole-blood samples were collected from 23 healthy volunteers 
(with and without diabetes mellitus) over a 6-day period. All participating persons gave 
informed consent to donate blood for the glucose measurements. A biomedical laboratory 
scientist collected capillary blood from a finger prick using ACCU-Chek Safe-T-Pro Plus 
(Roche Diagnostics), after wiping off the first blood drop. One finger prick was used when 
possible, but in some cases 2 and sometimes 3 finger pricks were needed to collect the 
required amount of capillary blood. For all the 23 patients, the sequence to collect capillary 
blood was as follows: First, 1 sample was collected for later analysis on the hospital 
instrument; the next samples were collected for analysis on the 7 POC instruments; and 
finally, a last sample was collected for later analysis on the hospital instrument. The time 
spent on each sequence varied between 5 and 14 min. The samples for use in the hospital 
instrument were collected in Microvette Lithium Heparin tubes (300 µL) (Sarstedt) and 
centrifuged immediately for 3 min at 10 000g (Minispin AG 5452 Model) to separate the 
plasma and to prevent glycolysis. The plasma was then frozen within the next 20 min at –
80°C and stored until analysis on the hospital instrument. The stability of the glucose 
concentration during sampling was examined by calculating the mean values for the duplicate 
capillary samples obtained at the start and end of each measurement sequence. The 
concentration was considered stable if the difference was <10% (10). All the patient samples 
had a difference <5% except 3 samples which had a difference of 5% to 8%. No significant 
difference was found between the first and the last glucose measurements (Student t-test, 
P>0.05). The glucose concentration in the whole-blood patient samples ranged from 72 to 432 




The CRP and Hb patient samples and the EQA material were analyzed in triplicate on the 
same day using the POC and hospital instruments. For CRP, serum samples were analyzed on 
the hospital instrument and EDTA whole-blood was analyzed on the POC instruments. For 
Hb, EDTA whole-blood samples were analyzed both on the POC instruments and on the 
hospital instrument. The measurements were performed at Noklus (POC) and at the 
laboratory of Haraldsplass Deaconess Hospital (hospital instruments). The patient samples 
were analyzed immediately after collection and the EQA material 2 days after production, 
stored 1 night in the refrigerator and additionally 1 night at room temperature to mimic the 
delay associated with mail delivery of the EQA material (Fig. 1). The EQA material and the 
patient samples for CRP were centrifuged before being analyzed using the Cobas 6000 
instrument. 
 
The glucose capillary whole-blood patient samples were analyzed in triplicate immediately 
after collection using the 7 POC instruments over a 6-day period. The same order of POC 
instruments was used in each measurement sequence. The EQA material was analyzed 2 days 
after production, including an overnight storage at room temperature to mimic mail delivery. 
All patient plasma samples were analyzed in one run on the hospital instrument on the same 
day. 
 
Internal quality control was performed at the beginning and end of each measurement 
sequence, which indicated that all of the POC instruments were stable throughout the analysis 
period for all analytes. In accordance with the EP14-A3 guideline (1), the fresh patient 
samples and the EQA material were analyzed in triplicate using all of the instruments.  
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STATISTICS 
The statistical analyses were performed according to the EP14-A3 guideline (1). A short 
overview is shown in Fig. 1. The data were first checked for outliers within the triplicate 
measurements. One outlier detected for each of glucose and Hb was excluded from further 
analysis, and no outliers were detected for CRP.  
 
When assessing the homogeneity of variance, the mean and SD of the triplicate measurements 
were presented in a scatter plot for each instrument, and if the plot revealed that SD increased 
with the analyte concentration, the results were log10-transformed. The results from 4 CRP 
instruments underwent log10 transformation to obtain homogeneity of the variance. All of the 
glucose and Hb results showed homogeneity of the variance.  
The linearity between the paired instruments was assessed visually using ordinary linear 
regression, which revealed that all of the instrument combinations showed linearity.  
 
Difference plots were displayed for every instrument combination, and log10 transformation 
was applied if the scattering increased with the concentration: This was done for 14 of 15 
CRP, 10 of 28 glucose, and 4 of 15 Hb instrument comparisons. The differences appeared 
constant in a second difference plot using the log10-transformed values, and so the log10-
transformed values were applied.  
 
Outliers between the methods were detected visually in the difference plots and excluded 
from the subsequent analysis. One outlier was excluded from 6 of the 15 CRP instrument 
combinations; 1 outlier was excluded from 3 of the 15 Hb instrument combinations; and 1 
outlier was excluded from 3 of the 28 instrument comparisons for glucose (i.e., 12 of 1349 
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data points were excluded) (see Fig. 1 in the Data Supplement that accompanies the online 
version of this article at http://wwwclinchem.org/content/vol65/issue6). 
 
Deming regression analyses using the mean of triplicate patient sample measurements (log10-
transformed or untransformed values) were performed for each analyte and each instrument 
combination. A 95% prediction interval (PI) was calculated and then plotted graphically along 
with the mean values of the triplicate measurements of the EQA samples (Fig. 2 here and also 
Fig. 2 in the online Data Supplement). The EQA material was assessed as being commutable 
if the means of each EQA sample were within or touching the PI limits; otherwise, it was 
considered noncommutable.  
 
The calculations were performed using the following packages of R software (version 3.1.2, R 
Development Core Team, 2007): MCR (method comparison regression, version 1.2.1), 
MethComp (functions for analyzing the agreement in method comparison studies, version 
1.22.2), and Boot (bootstrap functions, version 1.3.13).  
 
Results 
When the CRP and Hb POC instruments were compared with the hospital instruments, the 
EQA material was commutable for all instrument combinations except QuikRead GO at the 
highest CRP concentration (Fig. 2 and Table 1).  
 
For glucose, the EQA material was commutable between the hospital instrument and all of the 
POC instruments at the lowest concentration, but for the 2 higher concentrations, 
commutability was demonstrated for only the Contour and HemoCue instruments (Table 1).  
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Pairwise comparisons of the POC instruments revealed that the EQA material was 
commutable for nearly all instrument combinations for CRP and Hb, whereas 37 of 63 
combinations showed commutability with the EQA material for glucose, also mainly at the 
lowest concentration (see Table 1 in the online Data Supplement).  
 
Discussion 
This study examined the commutability of the Noklus whole-blood EQA material for CRP, 
glucose, and Hb POC instruments. The results showed that the EQA material can be 
considered commutable for CRP and Hb, as well for about half of the glucose POC 
instruments. 
 
Noklus aims to provide participants with EQA material that is as close to native patient 
samples as possible. However, for practical purposes, some constituents and stabilizers have 
to be added, which can jeopardize the commutability of the material (11). In the present EQA 
material, iodoacetic acid sodium salt in combination with EDTA and chloramphenicol 
succinate was used to stabilize the concentration of glucose, as iodoacetic acid has been 
shown to interfere less with whole-blood materials than does fluoride (12). However, it seems 
unlikely that any of these constituents contributed to the observed noncommutability seen 
between some of the instruments at some of the concentrations analyzed because the amounts 
of the components added were similar at all concentrations of the analytes in the EQA 
material. Thus, the only varying quantity was the concentration of the analytes themselves. 
However, because the analytes added were highly purified, it is difficult to understand that 
this could be the cause of the noncommutability (2).  
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The present study examined CRP and glucose at each of the 3 concentrations and Hb at 2 
concentrations. It is interesting that in all cases, the EQA material showed commutability for 
all analytes at the lowest concentration. This means that if only the lowest concentration had 
been examined, the EQA material would have been assessed as commutable for all POC 
instruments. This finding highlights the importance of including several concentrations when 
assessing the commutability of an EQA material. This aspect is also emphasized in the recent 
recommendations published by the IFCC working group on commutability (13). Those 
recommendations allow the inclusion of several concentrations and suggests that when 
assessing a panel of EQA materials, the EQA material should be individually evaluated at 
each concentration (13). For practical reasons, it cannot be expected, in an EQAS, that each 
concentration in each survey is examined for commutability. Additionally, the concentrations 
in the different surveys will always vary somewhat. Knowledge about when an EQA material 
is considered commutable or noncommutable (or at least the concentration ranges in which it 
can be considered commutable) is important for the EQA organizers. Therefore, for practical 
reasons, a discussion on how to apply the results from a commutability study in every day 
practice is needed. 
 
There is no agreed reference method for CRP, but the Cobas 6000 uses a method that is 
traceable to isotope dilution/GC-MS (ID/GC/MS), which is a method that fulfills all of the 
requirements for use as a higher-order reference measurement procedure. Additionally, the 
ERM/DA474/IFCC certified reference material (CRM) for CRP was used to validate the 
trueness of the Cobas 6000 (7). All CRP POC instruments showed commutability with the 
EQA material, except for QuikRead GO displaying borderline noncommutability at the 
highest concentration (Fig. 2 here and also Table 1 in the online Data Supplement). 
Nevertheless, because this CRP concentration is rather high and because the EQA material 
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shows commutability around the commonly used decision limits, Noklus has decided to 
calculate a common target value that is traceable to the CRM for all the CRP POC 
instruments.  
 
The reference ID/GC-MS method is available for glucose, but this method is not suitable for 
routine measurements due to the time-consuming sample preparation required (14). The 
Cobas 6000 used in the present study is traceable to the ID/GC-MS method (15), and 
additionally the trueness of the Cobas 6000 was verified using the SRM 965b (8). The results 
for the commutability of the glucose EQA material turned out to vary with the concentration. 
Three of the 7 POC instruments in this study showed commutability for all concentrations, 
and in theory a true value can be obtained for these instruments. However, it is difficult to 
explain to the participants that instruments for the same analyte will be evaluated against 
different types of target values; therefore, as a routine, a peer-group target value is still used in 
the Noklus EQAS. Nonetheless, Noklus will calculate the systematic deviation from the true 
target value for the commutable POC instruments, and this information will be communicated 
to the in vitro diagnostic (IVD) manufacturers and participants when needed.  
 
For Hb, a reference target value for the Noklus EQA evaluation is established by the Odense 
University Hospital (Odense, Denmark), which uses a cyanmethemoglobin reference method 
(16). Although based on a cyanide-free colorimetric method, the Advia 2120 used in the 
present study has been confirmed in EQASs as having good analytical quality. The Noklus 
EQA material showed commutability for all Hb POC instruments included in the present 
study; therefore, it can be evaluated using a common target value that is traceable to the 
reference method.  
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Miller et al. suggested a system of ranking into categories from 1 to 6 depending on the ability 
of an EQAS to evaluate the performance of participants and instruments (2). The results from 
the present study allow a target assignment based on the results for CRM for all of the CRP 
POC instruments and for 3 of the glucose POC instruments, and a target value assignment 
traceable to a reference measurement procedure for all Hb POC instruments. Thus, when 
using the Noklus EQA material, participants in the Noklus EQA program using these POC 
instruments can be categorized as using a category 1 scheme. Hence, the reproducibility, 
calibration traceability, and uniformity between participants and instruments can be evaluated 
(2). This is a considerable improvement, and it enhances the opportunity to guide both 
participants and the IVD industry, as well as contributing to achieving the goal of 
standardized and harmonized clinical laboratory results.  
 
The data evaluation was performed in the present study using the Deming regression model as 
advised by the EP14-A3 guideline (1). When using a linear model, the regression line (and 
therefore the PI) is determined by all of the data points for the selected population. The 
statistical approach suggested by the EP14-A3 guideline has been brought into question by 
the recent IFCC recommendations, which argue that the model might not be optimal when 
assessing the commutability of an EQA material (13). Whereas the IFCC suggests calculating 
the difference in bias between the EQA material and the patient samples along with error bars 
for the uncertainty (17), the CLSI method depends on visual inspection of where the data 
points for the EQA material are located in relation to the patient samples and the limits of the 
PI. In the present study, it was challenging to evaluate whether the data points were located 
on, or partly on, the limits of the PI in the commutability plots (Fig. 2 here and also Fig. 2 in 
the online Data Supplement), as the EP14-A3 guideline does not provide advice on how to 
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interpret such data points. Calculating error bars might have helped the evaluations, and 
slightly different conclusions could have been reached.  
 
The strengths of the present study are that it included the most commonly used POC 
instruments for CRP, glucose, and Hb in Norway. Because 99% of the Norwegian general 
practitioner clinics participate in Noklus, all CRP, glucose, and Hb laboratory instruments in 
primary healthcare were covered in this study. All of the patient samples were freshly 
collected and were not pooled before the analysis. Furthermore, all of the reagents used were 
from the same lot number in order to avoid any effects of between-lot variations (18, 19).  
 
A limitation of the present study is the predominance of patient samples covering the lowest 
concentration of glucose. The low availability of patient samples at higher concentrations 
made it difficult to obtain a sufficient number of samples in this range, and it may have 
contributed to the noncommutability observed at the higher glucose concentrations.  
 
In conclusion, the Noklus whole-blood EQA material was commutable for all the CRP and 
Hb POC instruments and for about half of the glucose POC instruments used in primary 
healthcare in Norway. As a consequence, the participants in Noklus now get their EQA CRP 
and Hb results evaluated against a common reference value. For glucose, owing to 
educational challenges, all participants will still get method-specific target values although 
true values for the commutable instruments are calculated and assessed by Noklus. The 
possibility to discover true systematic differences between the POC instruments can be 
disclosed, which enhances the EQA providers’ opportunity to give feedback to the IVD 
manufacturers and provide better guidance to the participants on which instrument to buy, as 
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well as improving the efforts to monitor standardization and harmonization of clinical 
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Table 1.  
Commutability of the Noklus whole-blood EQA material at different concentrations between 
the 5 CRP, 7 glucose, and 5 Hb POC instruments and the corresponding hospital instruments 
(Cobas 6000 and Advia 2120). 
 
 
CRP 23 mg/L 58 mg/L 73 mg/L 
Instrument Cobas 6000 Cobas 6000 Cobas 6000 
ABX Micros CRP 200 
(Horiba) 
C C C 
Afinion AS 100 Analyzer 
(Axis-Shield) 
C C C 
i-Chroma 
(BodiTech Med.Inc.) 
C C C 
NycoCard CRP Single Test 
(Axis-Shield) 
C C C 
QuikRead GO CRP+Hb 
(Orion Diagnostica) 
C C NC 
Glucose 126.0 mg/dL 





Instrument Cobas 6000 Cobas 6000 Cobas 6000 
Accu-Chek Performa 
(Roche Diagnostics) 
C NC NC 
Ascensia Contour 
(Bayer Healtcare) 
C NC NC 
Contour 
(Bayer Healtcare) 
C C C 
Contour XT 
(Bayer Healtcare) 
C NC NC 
FreeStyle Freedom Lite C NC NC 
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(Abbott Diabetes Care Inc) 
HemoCue Glucose 201+ 
(HemoCue AB) 
C C C 
HemoCue Glucose 201RT 
(HemoCue AB) 
C C C 
Hb 9.6 g/dl 13.2 g/dL  
Instrument Advia 2120 Advia 2120  
ABX Micros CRP 200 
(Horiba) 
C C  
HemoControl 
(EKF diagnostic GmbH) 
C C  
HemoCue Hb 201+ 
(HemoCue AB) 
C C  
Sysmex PocH-100i 
(Sysmex) 
C C  
QuikRead GO CRP+Hb 
(Simens Healtcare) 
C C  
 













Figure 1.  
The procedure for determining the commutability of the whole-blood EQA material for CRP, 
Hb, and glucose. The figure is modified from the CLSI EP14-A3 guideline (1).  
 
Figure 2.  
Examples of commutability plots for the whole-blood EQA material for 2 POC glucose (A 
and B), 1 POC CRP (C), and 1 POC Hb (D) instruments compared with the designated 
hospital instruments. Patient samples are indicated as grey squares, the EQA material as black 
dots, Deming regression lines as solid grey lines and the 95% prediction intervals as black 
dotted lines. 
 
